Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market
Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.
How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.
Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Why Galderma is turning ALASTIN into a clinic workflow strategy, not just a skincare brand
Galderma’s ALASTIN Signature Practices aim to embed skincare into aesthetic workflows. Read what this means for clinics, competition, and growth.
What Galderma’s nemolizumab phase II data mean for the competitive biologic landscape in pediatric eczema
Galderma’s nemolizumab phase II data in children aged 2-11 show 52-week itch and lesion relief. Read the analysis.
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.